Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839

被引：50

作者：

Albanell, J ^{[1
]}

Rojo, F ^{[1
]}

Baselga, J ^{[1
]}

机构：

[1] Univ Barcelona, Hosp Gen Valle Hebron, Med Oncol Serv, Barcelona 08035, Spain

来源：

关键词：

D O I：

10.1016/S0093-7754(01)90283-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：56 / 66

页数：11

共 54 条

[1] GROWTH-FACTORS AND CANCER
AARONSON, SA
[J]. SCIENCE, 1991, 254 (5035) : 1146 - 1153
[2] Albanell J, 2000, CLIN CANCER RES, V6, p4543S
[3] High telomerase activity in primary lung cancers: Association with increased cell proliferation rates and advanced pathologic stage
Albanell, J
Lonardo, F
Rusch, V
Engelhardt, M
Langenfeld, J
Han, W
Klimstra, D
Venkatraman, E
Moore, MAS
Dmitrovsky, E
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (21): : 1609 - 1615
[4] The ErbB receptors as targets for breast cancer therapy
Albanell, J
Baselga, J
[J]. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1999, 4 (04) : 337 - 351
[5] ALBANELL J, IN PRESS J CLIN ONCO
[6] ZD1839 ('Iressa')1,2 as an anticancer agent
Baselga, J
Averbuch, SD
[J]. DRUGS, 2000, 60 (Suppl 1) : 33 - 40
[7] Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
Baselga, J
Pfister, D
Cooper, MR
Cohen, R
Burtness, B
Bos, M
D'Andrea, G
Seidman, A
Norton, L
Gunnett, K
Falcey, J
Anderson, V
Waksal, H
Mendelsohn, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) : 904 - 914
[8] Baselga J, 2000, J CLIN ONCOL, V18, p54S
[9] Baselga J, 2000, PRINCIPLES PRACTICE, P475
[10] BASELGA J, 1999, P AM SOC CLIN ONCOL, V18, P619